Aesica Doubles Development Capacity
Aesica adds development capability at Queenborough with the opening of a new purpose-built facility.
Aesica Pharmaceuticals, a pharmaceutical contract development and manufacturing organization, announced on April 5, 2016 it has doubled its development capacity with the addition of the ability to manufacture multiple drug products up to Phase III clinical trials at its Queenborough facility.
Aesica is now able to develop and manufacture a customer product from early formulation development through clinical manufacture and commercialization.
According to a press announcement, the company’s highly potent and controlled drugs service offering has been expanded at Queenborough as a result of the new center. The company now offers full formulation and development capabilities in these specialist fields. The site handles highly potent drugs for any active up to SafeBridge Category 3, together with controlled drugs, with licenses for both schedules 2 to 4.
Source: Aesica
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
